STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more

This STAT Pharmalittle roundup covers two main items. At a four-hour FDA public meeting on Monday, doctors, veterans, pharmacists, and therapists urged the agency to establish clear safety and access standards for psychedelic therapies. The meeting was part of a months-long Trump administration push to bring qualified psychedelic drug programs to market, and discussion focused on practical issues including provider training and credentials, patient screening and monitoring, access and reimbursement, clinic capacity, and collecting long-term safety data.

In the second item, GSK has taken global rights to a multiple myeloma treatment developed by China's Chimagen Biosciences for up to $750 million. The deal centers on a "potential first-in-class" trispecific T-cell engager that GSK says is designed to target multiple myeloma cells well while offering improved safety compared with other TCEs for the blood cancer, which it says have had "difficult tolerability profiles." Chimagen's unidentified candidate is currently in preclinical-stage development and is due to start human testing next year.